Porcupine is a novel drug target that aims to address the issue of high unmet need in fibrosis.

Porcupine is a key enzyme in the WNT signalling pathway. WNT signalling has been implicated in fibrogenesis, and therefore inhibition of WNT signalling is likely to prevent several mechanisms important for fibrotic disease progression.

Current treatments for fibrosis are of limited benefit and there is an urgent need to develop new therapies to treat fibrotic conditions.

Several recent publications have shown that Porcupine (PORCN) inhibitors can be beneficial in the treatment of fibrotic indications, including renal, heart, lung and skin conditions.

Our team of scientists have demonstrated potent efficacy in mouse models of kidney, liver and lung fibrosis. Our candidate RXC006 has been nominated as a candidate for development in Idiopathic Pulmonary Fibrosis and IND-enabling studies have been initiated, with first-in-man studies expected to begin in 2021.

By targeting this pathway, we aim to prevent progression or reverse fibrosis in patients with these devastating diseases.

Porcupine inhibitor, RXC006 suppress fibrosis in a murine model of IPF

Image representative of group mean Ashcroft scores. Scale bar indicates 1.2 mm. Small region of dense collagenous connective tissue (fibrosis; black arrows demarcate) and lymphocyte infiltrates/aggregates (*) are present. A bronchiole (Br) and blood vessels (BV) are indicated.